explore -WSS

explore

author：explore 2025-09-30 17:30:06 - browse：484

Photograph of an abandoned lab with empty bottle, boxes, and beakers all around. -- biotech coverage from STAT — Adobe

SAN DIEGO — It was spring 2020, and Histogen, a small biotech with big ambitions to regenerate tissues throughout the body and turn a profit in the process, had just gone public. The company’s leadership believed they were poised for success — until everything slowly and irreversibly fell apart.

Three years later, Histogen no longer develops therapies. It has abandoned efforts to reverse baldness, replenish cartilage in achy knees, and quell infection and inflammation.

The company has no lab. It has no headquarters. It has just two employees, including a chief financial officer who also serves as secretary, CEO, and president. Histogen’s stock trades below $1 a share. And even that is coming to a close. On Thursday, the Nasdaq suspended trading of Histogen shares after determining that the company’s operations and assets are negligible, meaning the biotech is now officially a shell of its former self.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Impact of Dobbs ruling felt at reproductive medicine meeting

WSS

STAT Readout Newsletter: Today's biggest biotech updates

FDA warns J&J's Abiomed: We will regulate your software

FDA struggles to regulate food additives, sometimes for decades

In early work, researchers turn to CRISPR to treat Alzheimer's

Startup Neumora takes a novel depression drug to Phase 3

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

leisure time

explore

entertainment

Activists slam private health insurers over coverage restrictions

FDA gives detailed accounting of AI

FDA approval of Sarepta Duchenne genetic therapy gives me hope

As digital health tech proliferates, a new institute aims to cut through hype

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

CEOs share strategies for surviving biotech slump

New air purifier tech could be key to improving indoor air quality

Eli Lilly expects to double planned employment in Boston center

Tori Bowie and the unacceptable rates of Black maternal death

Senate committee scrutinizes Medicare Advantage brokers

explore

Sanofi seeks simpler, safer CRISPR sickle cell cure

Custom gene therapy hints at new path for rare disease treatments

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

STAT Summit: Michael J. Fox on progress in Parkinson's research

STAT Virtual Event: The State of Biosimilars: What to Watch

STAT Readout Newsletter: Today's biggest biotech updates

hotspot

hotspot

knowledge

explore